Headlines about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.8775746976619 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing (nasdaq.com)
- GEMPHIRE THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
- Gemphire Therapeutics Inc. (GEMP) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Analyzing Gemphire Therapeutics (GEMP) and Dimension Therapeutics (DMTX) (americanbankingnews.com)
GEMP has been the topic of several recent research reports. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Canaccord Genuity reaffirmed a “buy” rating on shares of Gemphire Therapeutics in a report on Friday, October 13th. Jefferies Group LLC lowered their price target on shares of Gemphire Therapeutics from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. HC Wainwright initiated coverage on shares of Gemphire Therapeutics in a report on Thursday, August 31st. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Roth Capital initiated coverage on shares of Gemphire Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Gemphire Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.00.
Shares of Gemphire Therapeutics (GEMP) opened at $8.96 on Tuesday. Gemphire Therapeutics has a 1-year low of $7.20 and a 1-year high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last posted its earnings results on Monday, August 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.28). analysts forecast that Gemphire Therapeutics will post -3.17 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Gemphire Therapeutics (GEMP) Share Price” was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2017/11/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-gemphire-therapeutics-gemp-share-price.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.